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ABSTRACT
Introduction: Major depressive disorder (MDD)
is an important risk factor for cardiovascular
mortality and morbidity. Red blood cell
distribution width (RDW) and
neutrophil/lymphocyte ratio (NLR) can be
obtained with a basic hemogram test. These
parameters have been found as a predictor of
mortality in the general population and in
several diseases such as cardiovascular disease.
Methods: Our study included 100 patients with
newly diagnosed MDD and 100 healthy control
patients (who had no depressive symptoms and
without heart disease) admitted to our
outpatient clinics. Patients with MDD were
started on selective serotonin reuptake
inhibitor (SSRI) treatment and followed up for
3 months. Both MDD and control patients’
laboratory tests and physical, neurological,
and psychiatric examinations were performed
both at diagnosis and after 3 months of
treatment.
Results: In total, 100 patients with MDD were
evaluated and 80 were included in our study.
The control group consisted of 91 healthy
individuals. The mean age was 44 ± 10.6 years
for patients with MDD and 39.8 ± 11.4 years for
the control group. There was no significant
difference between the age for groups
(P = 0.13); 55% of patients with MDD and
33% of the control group was male. NLR levels
were found to be 2.55 ± 0.7 and RDW levels
were found to be 14.3 ± 2.6 in patients with
MDD; NLR levels were found to be 1.41 ± 0.8
and RDW levels were found to be 13.4 ± 1.8 in
the control group. RDW and NLR levels were
significantly higher in patients with MDD
compared to the control group. The significant
difference between the levels of RDW and NLR
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in patients with MDD and the control group
was dissolved after SSRI treatment (P\0.001).
RDW [median 14.3, interquartile range (IQR)
2.8 vs. median 13.25, IQR 2.45; P\0.001] and
NLR (median 2.3, IQR 1.1 vs. median 2.0, IQR
1.15; P\0.001) levels were significantly higher
in patients with MDD compared to the control
group.
Conclusion: Our study showed that
hematological inflammatory markers might be
useful parameters that can be used in patients
with MDD for coronary artery disease risk.
Specifically, RDW and NLR seem to be more
hopeful. Advanced, detailed, and larger studies
are needed.
Keywords: Coronary artery disease; Major
depressive disorder; Mean platelet volume;
Neutrophil/lymphocyte ratio; Red cell
distribution width
INTRODUCTION
Major depressive disorder (MDD) is an
important risk factor for cardiovascular
morbidity and mortality [1, 2]. MDD increases
cardiac mortality in both patients with cardiac
disease and in healthy individuals [3]. The
underlying physiopathological mechanism
remains unclear. Several mechanisms have
been affirmed such as smoking and physical
inactivity [4, 5]. Some traditional risks factors
(hypertension, diabetes, and insulin resistance)
and nontraditional risk factors (increased
platelet reactivity, procoagulopathy,
inflammation and dysregulation of the
autonomic nervous system) for heart disease
have also been reported [6].
Red cell blood distribution width (RDW) and
neutrophil/lymphocyte ratio (NLR) can be
obtained with a basic hemogram test. These
parameters are cost effective, available, and
simply calculated. RDW is a parameter that
measures variation in red blood cell size or red
blood cell volume. It is usually used for
differential diagnosis of anemia, especially for
iron deficiency anemia [7]. RDW has been
shown to be a predictor of mortality in the
general population [8] and in several diseases
such as acute and chronic heart failure [9, 10],
acute pulmonary embolism [11], myocardial
infarction [12], peripheral arterial disease [13],
and acute renal failure [14]. It has been shown
that the rate of NLR gets higher as a response to
systematic inflammation in stress. It has a
prognostic importance in chronic
inflammation such as cardiovascular disease,
malignancies, ulcerative colitis, and hepatic
cirrhosis [15, 16].
The relationship between plasma levels of
RDW and NLR in patients with MDD has not
yet been established. In this study, we aimed to
investigate the relationship between these
parameters and presence of MDD. Another
objective was to evaluate the effect of selective
serotonin reuptake inhibitor (SSRI) treatment
on RDW and NLR levels in patients with MDD.
METHODS
Patients
Our study included 100 patients with newly
diagnosed MDD and 100 control patients
admitted to our outpatient clinics for routine
examination. Control patients consisted of
people who did not meet the exclusion criteria
and without depressive symptoms. Control
group age and gender characteristics were
closed. We followed up with these patients
from August to November 2014. Patients were
evaluated both at diagnosis and after 3 months
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of treatment. All patients signed consent forms
to participate in this study. The study protocol
was approved by the ethics committee of Firat
University, Faculty of Medicine, Elazig, Turkey.
The study was conducted in accordance with
the Declaration of Helsinki.
Clinical Examination
All patients were questioned for medical
history. Physical, neurological, and psychiatric
examinations were done, and laboratory test
was performed for both patients with MDD and
healthy control individuals at first diagnosis
and after 3 months of treatment.
Biochemical Measurements
Fasting venous blood samples were collected in
the morning after 8 h of fasting. The assays were
performed at the laboratory in Cagri Private
Medical Center and Firat University’s Faculty of
Medicine using a biochemical analyzer (ABX
Pentra DX 120; HORIBA, Ltd.). Hemograms
were determined with an autoanalyzer
(Coulter LH 780 hematology system;
Beckman Coulter, Inc.). The blood samples
were processed within 30 min after blood
collection. Baseline NLR was measured by
dividing absolute neutrophil count by absolute
lymphocyte count.
Diagnosis and Exclusion Criteria
The Diagnostic and Statistical Manual of Mental
Disorders, 4th Edition’s (DSM-IV) criteria were
used for diagnosing MDD. The
Montgomery–A˚sberg Depression Rating Scale
(MADRS) [17] was used for assessing the
severity of depression and the effectiveness of
the treatment. Patients with cardiovascular
disease, hepatic or renal failure, previously
detected malignancies, diabetes mellitus,
hyperthyroidism, pregnancy, chronic
obstructive pulmonary disease, or who were
smokers or using anticoagulant–antiplatelet
medications were excluded from the study.
Hemoglobin \13 g/dL for males and \12 g/dL
for females, and white blood cell counts
[12,000 cells and \4000 cells were ignored.
Laboratory tests were repeated after 3 months.
Treatment
Patients with MDD were treated with SSRIs
(escitalopram and sertraline) for 3 months.
Escitalopram was dosed from 10 to 20 mg/day
and sertraline was dosed from 25 to
100 mg/day.
Statistical Analysis
All statistical analyses were performed with the
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
The significance of the mean differences
between groups was assessed by Student’s
t test. Also, paired t test was used for repeated
data in the patient group. Data were presented
as mean ± standard deviation. Relationships
between variables were tested using Pearson’s
correlation analysis. Receiver operating
characteristic (ROC) curve graphics were used
in the comparison of sensitivity and specificity.
P values less than 0.05 were regarded as
significant.
RESULTS
A total of 100 patients with MDD were
evaluated and 80 patients were included in the
study. The control group consisted of 91
healthy individuals. Mean age was
44 ± 10.6 years in patients with MDD and
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39.8 ± 11.4 years in the healthy control group.
There was no significant difference between the
mean age of the groups (P = 0.13); 55% of
patients with MDD and 53.8% of the healthy
control group were male. The demographic and
gender distributions of the subjects are
summarized in Table 1.
NLR levels were found to be 2.55 ± 0.7 and
RDW levels were found to be 14.3 ± 2.6 in
patients with MDD; NLR levels were found to be
1.41 ± 0.8 and RDW levels were found
13.4 ± 1.8 in the control group. RDW and NLR
levels were significantly higher in patients with
MDD compared to the control group. The
significant difference between the levels of
RDW and NLR in patients with MDD and the
control group was dissolved after SSRI treatment
(P\0.001). Baseline RDW levels and NLR of the
groups are shown in Table 2.
RDW [median 14.3, interquartile range (IQR)
2.8 vs. median 13.25, IQR 2.45; P\0.001] and
NLR (median 2.3 IQR 1.1 vs. median 2.0, IQR
1.15; P\0.001) levels were significantly higher
in patients with MDD compared to the control
group. ROC analysis revealed that an RDW
measurement higher than 95% predicted
depression with a sensitivity of 60% and a
specificity of 58% in the study population (area
under the curve 0.62, P = 0.007). The cutoff
value for NLR for diagnosis of MDD in the study
population was 2.05 (Fig. 1).
In patients with MDD, platelet counts were
186.6 ± 66 9 109/L and mean platelet volume
(MPV) levels were 10.3 ± 1.5 fl. In the control
group, platelet counts were
190.1 ± 69.7 9 109/L and MPV levels were
9.6 ± 1.2 fl. MPV levels were significantly
higher in MDD group (P\0.001) and
significantly decreased after SSRI treatment
when compared to the basal level
(P\0.001). The platelet counts were lower in
patients with MDD as compared to the
control group, but the difference was not
significant (P = 0.17). No significant
difference was observed in platelet counts
after treatment. The parameters are reported
in Table 3.
The significant differences between the levels
of RDW, MPV, and NLR in the MDD and
control groups were dissolved after the SSRI
treatment (P\0.001). The effects of treatment
on laboratory parameters in patients with MDD
are given in Table 3.
DISCUSSION
Patients with MDD are at an increased risk for
cardiovascular disease [1, 2]. The underlying
mechanism is not clearly known. Multiple
mechanisms are involved in the relationship
between MDD and ischemic cardiac disease.
There is no serum marker for the diagnosis of
depression. An increased RDW level is expected
in inflammatory and infectious pathologies due
to release of premature reticulocytes into the
circulation. On the contrary, Narci et al. [18]
found lower RDW levels in patients with acute
appendicitis compared to controls. They
suggested this finding may be the result of
greater RDW levels in chronic inflammatory
diseases compared to that in acute conditions
[18].
Table 1 The demographic and gender distributions of the







Age (years) 44.10 ± 10.60 39.80 ± 11.50 0.013
Male (n/%) 44/55% 49/53.8% 0.004
Female (n/%) 36/45% 42/46.2% 0.004
MDD major depressive disorder
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Lymphocytes play a major role in chronic
inflammation. Lymphocytes infiltrating the
ischemic and re-perfused tissue and may have
a significant role in healing. The relative
lymphopenia observed in patients with acute
ischemia is considered to be a stress response as
a result of increased endogenous cortisol [19].
NLR is a hematologic parameter that is studied
the most. Like other hematological
inflammatory markers, most studies focus on its
prognostic power. It was found to be a simple,
readily available, inexpensive, and independent
predictor marker for various cardiovascular
diseases, such as stable coronary artery disease,
acute coronary syndromes, and heart failure [20].
Previous studies demonstrate that serotonin
affects immunological response like
inflammation by affecting proliferation of
lymphocyte [21, 22]. NLR significantly
Table 2 Baseline RDW levels and NLR of the study groups
Patients with MDD (n5 80) Control group (n5 91) P value
NLR 2.55 ± 0.70 1.41 ± 0.8 \0.001
RDW 14.30 ± 2.60 13.30 ± 1.2 0.001
PLT (9109/L) 186.60 ± 66.10 190.10 ± 69.7 0.53
MPV (ﬂ) 10.30 ± 1.50 9.10 ± 1.2 \0.001
MDD major depressive disorder, MPV mean platelet volume, NLR neutrophil/lymphocyte ratio, PLT platelet, RDW red
blood cell distribution width
Fig. 1 Curve of NLR, RDW, PLT, and MPV levels in
patients with major depressive disorder. Diagonal segments
are produced by ties. MPV mean platelet volume, NLR
neutrophil/lymphocyte ratio, PLT platelet, RDW red
blood cell distribution width, ROC receiver operating
characteristic
Table 3 Before and after treatment levels of RDW and NLR in patients with major depressive disorder
Before treatment After treatment P value
NLR 2.55 ± 0.70 2.03 ± 0.7 \0.001
RDW 14.30 ± 2.60 13.40 ± 1.8 \0.001
PLT (9109/L) 186.60 ± 66.10 190.10 ± 69.7 0.71
MPV (ﬂ) 10.30 ± 1.50 9.60 ± 1.2 \0.001
MPV mean platelet volume, NLR neutrophil/lymphocyte ratio, PLT platelet, RDW red blood cell distribution width
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decreasing after SSRI treatment in our study also
supported this hypothesis.
As far as we know, our study is the first
case–control study that assesses the diagnostic
capability of hematologic inflammatory
markers to define depression. We showed that
hematological inflammatory markers’ levels like
RDW levels and NLR are found to be higher in
patients with MDD than healthy controls, and
maybe a valuable tool for the discrimination.
Decreasing levels of RDW and NLR after SSRI
treatment suggests that these medications may
have an anti-inflammatory effect.
In conclusion, our study showed that
hematological inflammatory markers might be
useful parameters that can be used in MDD
patients for coronary artery disease risk;
especially RDW and NLR seems to be more
hopeful. Advanced, detailed and larger studies
are needed.
Limitations
The present study has several limitations. For
instance, the sample size was not calculated
before enrolling participants in the study. Other
SSRI drugs could be studied and patients could
be divided into two groups, one using
escitalopram and another using sertraline.
Body mass index, blood pressure, and
biological markers were not compared with
the severity of depression.
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